First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients

YÜKSEL, SELÇUK; Evrengul, Havva; ÖZÇAKAR, ZEYNEP; Becerir, Tulay; Yalcin, Nigihan; Korkmaz, Emine; ÖZALTIN, FATİH

doi:10.1007/s40272-016-0194-0

First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients

Atıf İçin Kopyala

YÜKSEL S., Evrengul H., ÖZÇAKAR Z. B., Becerir T., Yalcin N., Korkmaz E., ...Daha Fazla

PEDIATRIC DRUGS, cilt.18, sa.6, ss.413-420, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 18 Sayı: 6
Basım Tarihi: 2016
Doi Numarası: 10.1007/s40272-016-0194-0
Dergi Adı: PEDIATRIC DRUGS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.413-420
Hacettepe Üniversitesi Adresli: Evet

Özet

Studies relating to first-line, early, and long-term eculizumab treatment and outcomes in children with atypical hemolytic uremic syndrome (aHUS) are scarce and unclear. The aim of this case-series study was to evaluate the outcomes of first-line, early, and long-term eculizumab treatment in our aHUS patients.